Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Oct 3;37(33):3142–3151. doi: 10.1200/JCO.19.00489

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 by American Society of Clinical Oncology

PMC Copyright notice

FIG 2. — Kaplan-Meier estimates of (A and B) progression-free survival (PFS) and (C and D) overall survival (OS) for the different BRAF genotypes V600 (A and C) and non-V600 (B and D) in reference to their treatment (BRAF inhibitor [BRAFi]/MEK inhibitor [MEKi] combination [blue line], BRAFi monotherapy [red line], and MEKi monotherapy [green line]). In BRAFi/MEKi versus BRAFi alone, there was a significant difference in median PFS for rare V600 mutations (8 months v 3.7 months) and OS (17.3 months v 7.3 months; P ≤ .05; A and C). In the non-V600 group, no difference was observed for BRAFi/MEKi combination or monotherapy (B and D). Median PFS was longer for BRAFi/MEKi combination and MEKi monotherapy compared with BRAFi monotherapy.